OCULAR THERAPEUTIX, INC Accrued Liabilities, Current
OCULAR THERAPEUTIX, INC (OCUL) had Accrued Liabilities, Current of $39.06 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-03
- 2026-06-30: Accrued Liabilities, Current $39.06M.
- 2026-03-31: Accrued Liabilities, Current $36.49M.
- 2025-12-31: Accrued Liabilities, Current $43.84M.
- 2025-09-30: Accrued Liabilities, Current $40.27M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $39.06M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $36.49M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $43.84M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $40.27M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $34.42M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $31.08M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $35.12M 10-K · filed 2026-02-05 |
| 2024-09-30 | $30.45M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $24.36M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $16.04M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $28.67M 10-K · filed 2025-03-03 |
| 2023-09-30 | $28.89M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $24.60M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $21.99M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $24.10M 10-K · filed 2024-03-11 |
| 2022-09-30 | $21.61M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $19.45M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $17.64M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $20.12M 10-K · filed 2023-03-06 |
| 2021-09-30 | $19.36M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $16.18M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $13.57M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $14.31M 10-K · filed 2022-02-28 |
| 2020-09-30 | $12.16M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $5.77M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $5.02M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $7.63M 10-K · filed 2021-03-11 |
| 2019-09-30 | $6.47M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $5.06M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $4.04M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $6.19M 10-K · filed 2020-03-12 |
| 2018-09-30 | $4.54M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $3.68M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $3.60M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $4.31M 10-K · filed 2019-03-07 |
| 2017-09-30 | $4.35M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $4.38M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $4.00M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $4.63M 10-K · filed 2018-03-08 |
| 2016-09-30 | $2.79M 10-Q · filed 2016-11-09 |
| 2016-06-30 | $2.34M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.78M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $3.38M 10-K · filed 2017-03-10 |
| 2015-09-30 | $3.59M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $2.28M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $1.92M 10-Q · filed 2015-05-15 |
| 2014-12-31 | $3.02M 10-K · filed 2016-03-10 |
| 2014-09-30 | $2.48M 10-Q · filed 2014-11-12 |
| 2014-06-30 | $1.63M 10-Q · filed 2014-08-29 |
| 2013-12-31 | $741.00K 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |